Alamar Biosciences Stock Soars on 82% Revenue Growth and Upgraded Forecast

Alamar Biosciences stock surged in pre-market trading after the company reported a significant acceleration in revenue for its second quarter and raised its full-year financial guidance well above Wall Street expectations. The life sciences firm's shares climbed 10.3% to reach $38.44 ahead of the market open, nearing a 52-week high.

Blockbuster Results Fuel Rally

The rally was sparked by the company's second-quarter 2026 financial results, which revealed revenue climbing approximately 82% year-over-year to $29.4 million. Alamar also posted a record gross margin of 60%, indicating improved profitability alongside its rapid top-line growth.

Following the strong performance, management raised its full-year 2026 revenue guidance to a new range of $116 million to $120 million. This updated forecast, which implies year-over-year growth of roughly 59%, surpassed the prior analyst consensus and reset expectations for the company's commercial trajectory.

Analyst Upgrades and Strategic Partnership

The impressive earnings report prompted a wave of positive revisions from investment banks. Several analysts covering the stock raised their price targets while maintaining positive ratings:

Ad

• JPMorgan: to $35
• TD Cowen: to $34
• Stifel: to $32
• Bank of America: to $31

Adding to the bullish sentiment, Alamar announced an expanded partnership with the Alzheimer’s Disease Data Initiative alongside its earnings. The collaboration serves as a high-profile validation for its NULISA proteomics platform in a critical and commercially significant area of biopharmaceutical research.

Market Context

The stock's advance was supported by a constructive backdrop in the broader market, which tends to amplify moves in high-growth life science names. The gains appear to be company-specific, as no material news from direct competitors was reported. The combination of strong fundamental performance, a positive forecast, analyst endorsements, and a key strategic development has created significant momentum for the stock.